Ovarian cancer (OC) remains one of the deadliest gynecological malignancies, primarily due to the frequent development of chemoresistance and the lack of predictive tools to guide treatment decisions. Malignant ascites (MA), often seen in advanced OC patients, serves as a valuable ex vivo model for assessing drug efficacy in a relevant microenvironment. This project aims to create a rapid, high-throughput ex vivo assay to evaluate the therapeutic potential of various compounds on OC cells. The project consists of two interdependent tasks. First, high-throughput screening (HTS) with a 1200-compound library will target chemoresistant OC cell lines to identify therapeutic candidates. Next, the identified "hits" will be validated in additional OC cell lines using 2D and 3D cultures, cell microarray, and immunocytochemistry analyses. Finally, the most promising compounds will be tested ex vivo with fresh MA-derived cells and autologous supernatants to evaluate drug responses in a physiologically relevant environment. By integrating HTS, in vitro validation, and ex vivo testing, this project seeks to bridge the gap between basic screening models and the clinical complexity of OC.